<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02104700</url>
  </required_header>
  <id_info>
    <org_study_id>Near Rwanda</org_study_id>
    <secondary_id>ISR-In-US-264-0123</secondary_id>
    <nct_id>NCT02104700</nct_id>
  </id_info>
  <brief_title>Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir</brief_title>
  <acronym>Near-Rwanda</acronym>
  <official_title>Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Grant</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be an open-label, pilot study in virologically suppressed patients comparing&#xD;
      the efficacy, safety and tolerability of two Antiretroviral regimen strategies:&#xD;
&#xD;
      Arm A: &quot;Immediate switch&quot; Rilpivirine/Emtricitabine/Tenofovir (single tablet formulation&#xD;
      (STF))at randomization&#xD;
&#xD;
      Arm B: &quot;Delayed switch&quot; Continue Nevirapine/Lamivudine/other Nucleoside reverse transcriptase&#xD;
      inhibitor (NRTI)through 24 weeks then switch to STF of Rilpivirine/emtrictabine/tenofovir and&#xD;
      followed through 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study is designed to be the first study to compare a continued nevirapine-based&#xD;
      regimen to a switch to the FDC of rilpivirine/emtricitabine/tenofovir. Rwanda is a model&#xD;
      country for implementation of newer approaches to more innovative ART strategies with an&#xD;
      excellent National HIV Treatment program in place but has limited experience with clinical&#xD;
      trials and as with most African countries has no clinical experience with Rilpivirine in&#xD;
      treating HIV infected adults. Done in collaboration with Rwanda Biomedical center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Explore Efficacy</measure>
    <time_frame>24 weeks</time_frame>
    <description>To compare proportion of subjects successfully maintaining a plasma viral load &lt;200 copies /mL at week 24 in subjects randomized to rilpivirine/emtricitabine/tenofovir vs. in those randomized to initially continue nevirapine-based ART in this pilot study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV RNA levels</measure>
    <time_frame>24 weeks</time_frame>
    <description>To compare between arms the probability of having an HIV RNA level &lt;50 and &lt;400 copies/mL at 24 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Rilpivirine/Emtricitabine/Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Immediate switch&quot;: RILPIVIRINE/ EMTRICITABINE /TENOFOVIR FDC QDAY at randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nevirapine/Lamivudine/ plus other NNRTI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&quot;Delayed switch&quot;: Continue NEVIRAPINE 200MG BID + LAMIVUDINE 300MG + OTHER NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NRTI) through 24 weeks then switch to RILPIVIRINE 25MG/ EMTRICITABINE 200MG/TENOFOVIR 300MG FDC QDAY and then follow through 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilpivirine/Emtricitabine/Tenofovir</intervention_name>
    <description>Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday</description>
    <arm_group_label>Nevirapine/Lamivudine/ plus other NNRTI</arm_group_label>
    <arm_group_label>Rilpivirine/Emtricitabine/Tenofovir</arm_group_label>
    <other_name>Complera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infection, as documented by any licensed ELISA test kit and confirmed by Western&#xD;
             blot at any time prior to study entry. A second antibody test by a method other than&#xD;
             ELISA is acceptable as an alternative confirmatory test or a previous detectable HIV&#xD;
             RNA level&#xD;
&#xD;
          -  HIV RNA level below the limit of quantification of the viral load assay in use&#xD;
             in-country within the last 12 months&#xD;
&#xD;
          -  Screening HIV RNA level below the limit of quantification as defined by the local&#xD;
             assay&#xD;
&#xD;
          -  At least twelve months of stable first-line antiretroviral therapy consisting of&#xD;
             nevirapine and 2 nRTIs approved by the Rwandan HIV Treatment guidelines. (No prior&#xD;
             changes in ART are allowed)&#xD;
&#xD;
          -  Enrolled in the Rwanda National ART Program with no in-country transfer within the&#xD;
             program.&#xD;
&#xD;
          -  Negative TB symptom screen or eligible based on algorithm outlined in&#xD;
&#xD;
          -  Laboratory values obtained within 30 days prior to study entry:&#xD;
&#xD;
               -  Hemoglobin greater than 8.0 g/dL&#xD;
&#xD;
               -  Platelet count greater than 40,000/mm3&#xD;
&#xD;
               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase less than 5 X ULN&#xD;
&#xD;
               -  Total bilirubin less than 2.5 x ULN&#xD;
&#xD;
               -  Calculated creatinine clearance greater than 60 mL/min as estimated by the&#xD;
                  Cockcroft-Gault equation:&#xD;
&#xD;
                    -  Ability to meet the nutritional requirements for rilpivirine; largest meal&#xD;
                       should consist of at least 400 total kcals and 117 kcals of fat (13 grams)&#xD;
                       to be assessed at screening.&#xD;
&#xD;
                    -  For women of reproductive potential, negative serum or urine pregnancy test&#xD;
                       within 4 weeks of initiating study medications and a negative urine&#xD;
                       pregnancy test at the entry visit prior to randomization.&#xD;
&#xD;
          -  &quot;Women of reproductive potential&quot; is defined as women who have not been&#xD;
             post-menopausal for at least 24 consecutive months (i.e., who have had menses within&#xD;
             the preceding 24 months) and have not undergone surgical sterilization (e.g.,&#xD;
             hysterectomy, bilateral oophorectomy, or tubal ligation).&#xD;
&#xD;
          -  Age greater than18 years.&#xD;
&#xD;
          -  Ability and willingness of subject to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of on-treatment virologic failure (defined as HIV RNA level greater than 200&#xD;
             copies/mL at or after 6 months of antiretroviral therapy)&#xD;
&#xD;
          -  Any change in prior ART.&#xD;
&#xD;
          -  Currently breastfeeding.&#xD;
&#xD;
          -  Active tuberculosis.&#xD;
&#xD;
          -  Serious illness requiring systemic treatment and/or hospitalization until candidate&#xD;
             either completes therapy or is clinically stable on therapy, in the opinion of the&#xD;
             site investigator, for at least 14 days prior to study entry.&#xD;
&#xD;
          -  NOTE: Isolated cutaneous Kaposi's Sarcoma, oral candidiasis, vaginal candidiasis,&#xD;
             mucocutaneous herpes simplex, and other non-serious illnesses (as judged by the site&#xD;
             investigator) have no restriction.&#xD;
&#xD;
          -  Known allergy/sensitivity to study drugs or their formulations.&#xD;
&#xD;
          -  Active drug or alcohol use or dependence that, in the opinion of the site&#xD;
             investigator, would interfere with adherence to study requirements.&#xD;
&#xD;
          -  Requirement for any current medications that are prohibited with any study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Zolopa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rwanda Military Hospital</name>
      <address>
        <city>Kinombe</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Rwanda</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 1, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Philip Grant</investigator_full_name>
    <investigator_title>Associatge Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

